Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 230 participants.

Also called NCT02089126

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 230 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02089126
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02089126. Randomized; triple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2016-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Gemigliptin/Glimepiride combination
Lead sponsor
LG Life Sciences (class: industry)

Record details

Record id
cardio:ct-nct02089126
Content hash
567c8065a9ae1aa9acdc5d697bfedb08ede95a25c33c35659c0ff322e0223d07